Earl Pineda is based in France and is currently managing the Field Applications team for Europe and Asia at Repligen.  Earl has been in the biotech industry for about 20 years, and since working at Refine Technologies and now at Repligen, he has helped hundreds of companies successfully implement the XCell® ATF technology all over Europe and Asia over the past 13 years.  He has previously worked at major biotech companies like Amgen, Novartis, and Biomarin, within different research functions in process development, MSAT, and tech transfer teams.  An expert in perfusion process, Earl has vast experience with cell retention technologies, including ATF, TFF, gravitational cell settlers, acoustic cell retention, and microcarrier-based systems.  At Biomarin, Earl helped develop several now commercial perfusion processes for Aldurazyme and Naglazyme.  At Refine and Repligen, Earl has helped develop the Single-use ATF and has also designed the user interfaces for several ATF controllers, including C24 and the new XCell Lab and XCell Large Scale.